In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin.
Mupirocin and amoxicillin-clavulanate were synergistic against 9 of 49 (18%) strains of methicillin-resistant and methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci (CNS). A pattern of enhanced killing was also found using time-kill studies. Time-kill assays were more discriminatory than chequerboard titration assays in demonstrating synergy. These results suggest that combinations of amoxicillin-clavulanate and mupirocin may have therapeutic benefits in prophylaxis against staphylococcal infections.
Alou
Luis
L
Departmento de Microbiología I, Facultad de Medicina, Avda Complutense s/n, 28040 Madrid, Spain.
Cafini
Fabio
F
Sevillano
David
D
Unzueta
Irune
I
Prieto
José
J
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D003030:Coagulase / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D016712:Mupirocin / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000517:prevention & control; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D003030:Coagulase; D019980:Amoxicillin-Potassium Clavulanate Combination; D016712:Mupirocin